Fennec ’s $20M offering primes company for 2019 commercial launch

With a new drug application filing just within reach, Research Triangle Park-based Fennec Pharmaceuticals ’ (Nasdaq: FENC) $20 million public offering aims to prepare the company for a commercial launch in 2019.  Fennec – which is developing a product called PEDMARK for the prevention of hearing loss in pediatric cancer patients receiving chemotherapy – announced Friday the pricing of its public offering of about 2.3 million common shares at a price of $8.50 per share.  “The proceeds are…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news